| Gene symbol | IL13RA2 | Synonyms | CD213A2, CT19, IL-13R, IL13BP | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq23 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | interleukin 13 receptor subunit alpha 2 | ||||
| GTO ID | GTC2201 |
| Trial ID | NCT04119024 |
| Disease | Susceptibility to Cutaneous Malignant Melanoma 3 |
| Altered gene | IL13RA2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | IL13Ra2 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma |
| Year | 2019 |
| Country | United States |
| Company sponsor | Jonsson Comprehensive Cancer Center |
| Other ID(s) | 19-001145|NCI-2019-05764|19-001145 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||
|
|||||||||||